Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NCF1 | P14598 | 1/20 | 0.53 |
| ▸ | HRH3 | Q9Y5N1 | 8/20 | 0.46 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | MBTD1 | Q05BQ5 | 1/20 | 0.41 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3242381 | 0.99 | NCF1 (0.51) | NCF1HRH3HRH4SMN1; SMN2ALDH1A1 | |
| SCHEMBL3245819 | 0.90 | CHKA (0.53) | NCF1HRH3KDM4E | |
| SCHEMBL3240480 | 0.86 | CASR (0.45) | NCF1SMN1; SMN2ALDH1A1KDM4E | |
| SCHEMBL13323461 | 0.80 | NCF1 (0.68) | NCF1HRH3HRH4SMN1; SMN2ALDH1A1 | |
| SCHEMBL21730434 | 0.79 | NCF1 (0.66) | NCF1HRH3HRH4SMN1; SMN2ALDH1A1 | |
| SCHEMBL302270 | 0.78 | HRH3 (0.74) | NCF1HRH3HRH4SMN1; SMN2ALDH1A1 | |
| SCHEMBL2265992 | 0.77 | HRH3 (0.78) | NCF1HRH3HRH4SMN1; SMN2ALDH1A1 | |
| SCHEMBL4429235 | 0.77 | HRH3 (0.78) | NCF1HRH3HRH4SMN1; SMN2ALDH1A1 | |
| SCHEMBL1334239 | 0.75 | HRH3 (0.75) | NCF1HRH3HRH4SMN1; SMN2ALDH1A1 | |
| SCHEMBL4547890 | 0.73 | HRH3 (0.65) | NCF1HRH3HRH4SMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100144733-A1 | Compounds, compositions and methods comprising heteroaromatic derivatives | INSTITUTE FOR ONEWORLD HEALTH | 2010-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100144733-A1 | Compounds, compositions and methods comprising heteroaromatic derivatives | CFTR, PKD1, PKD2 | NCF1 1244/4885HRH3 2578/4885HRH4 872/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.